Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harsh Shah

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I StudyDeborah M Stephens, Ying Huang, Amy S Ruppert, et al.
ATS Scholar|August 4, 2022
A Multicenter Study Assessing Interventional Pulmonary Fellow Competency in Electromagnetic Navigation BronchoscopyHans J Lee, A Christine Argento, Hitesh Batra, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 28, 2026
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin LymphomaDaniel Ermann, Victoria Vardell, Erin Zacholski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
Haematologica|April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomesCharlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
American Journal of Hematology|January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Michael A Spinner, Kevin David, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I StudyDeborah M Stephens, Ying Huang, Amy S Ruppert, et al.
ATS Scholar|August 4, 2022
A Multicenter Study Assessing Interventional Pulmonary Fellow Competency in Electromagnetic Navigation BronchoscopyHans J Lee, A Christine Argento, Hitesh Batra, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 28, 2026
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin LymphomaDaniel Ermann, Victoria Vardell, Erin Zacholski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
Haematologica|April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomesCharlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
American Journal of Hematology|January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Michael A Spinner, Kevin David, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Pageof 11